594844-39-0Relevant academic research and scientific papers
Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY
-
Paragraph 0299-0301, (2019/03/05)
Disclosed herein is a tri-substituted phenyl Btk inhibitors with improved dual selectivity, a method and a composition for inhibiting Btk and treating disease associated with undesirable Btk activity (Btk-related diseases).
SPIROINDOLINONE PYRROLIDINES
-
Page/Page column 59, (2011/06/23)
There are provided compounds of the formula wherein X, Y and R1 to R8 are described herein along with the enantiomers, pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.
THIAZOLYL-DIHYDRO-INDAZOLES
-
Page/Page column 62, (2009/10/22)
The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
-
Page/Page column 49-50, (2009/09/28)
The invention relates to pyridopyrimidinone compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of Plk1.
ESTER DERIVATIVE AND MEDICINAL USE THEREOF
-
Page/Page column 82, (2010/11/08)
A therapeutic agent for hyperlipidemia which has no side effects on the liver unlike conventional MTP inhibitors and has excellent MTP inhibitory activity. Also, provided is an ester compound represented by the general formula (1): or a pharmaceutically a
ESTER COMPOUND AND MEDICINAL USE THEREOF
-
Page 150, (2008/06/13)
A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1") (wherein ???R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; ???X is -COO- or -CON(R10)-; ???R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R8 and R9 are each independently hydrogen atom, C1-C6 alkyl, -CON(R18)(R19) or -COO(R20), etc.; ???ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; ???Alk1 and Alk2 are each independently alkanediyl, etc.; ???l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.
